Generic Name and Formulations:
Carboplatin 10mg/mL; soln for IV infusion.
Various generic manufacturers
Indications for Carboplatin:
Initial treatment of advanced ovarian cancer in combination with other chemotherapy. Secondary treatment of recurrent ovarian cancer after prior chemotherapy, including patients previously treated with cisplatin.
See literature. Give by IV infusion over ≥15 minutes. Combination therapy with cyclophosphamide (previously untreated): 300mg/m2 on Day 1 every 4 weeks for 6 cycles. As a single agent for recurrent ovarian carcinoma: 360mg/m2 on Day 1 every 4 weeks. In either case the Calvert equation may be used (Total Dose [mg]=[target area under the curve (AUC)] X [glomerular filtration rate + 25]). Use Calvert equation for elderly patients. Adjust dose for renal insufficiency and blood counts (see literature).
Severe bone marrow suppression. Significant bleeding. Pregnancy (Cat.D). Nursing mothers.
Dose-related bone marrow suppression. Elderly. Renal dysfunction. Monitor blood counts frequently; do not repeat dose until neutrophil count is >2,000 and platelets are >100,000. Anemia (transfusions may be needed). Premedicate with antiemetics; increasing infusion time or dividing total daily dose over 5 days may reduce emesis. Previous platinum-containing therapy. Loss of vision with higher than recommended doses.
Potentiates nephrotoxicity with other nephrotoxic drugs (eg, aminoglycosides). Caution with other myelosuppressives.
Platinum coordination complex.
Bone marrow suppression with possible infectious or hemorrhagic complications, anemia, vomiting, abdominal pain, anorexia, diarrhea, constipation, peripheral neuropathies, ototoxicity, visual disturbances, taste perversion, CNS symptoms, nephrotoxicity, hepatotoxicity, electrolyte changes, hypersensitivity reactions, injection site reactions, pain, asthenia, alopecia, malaise, hypertension; respiratory, genitourinary, mucosal, cardiovascular events; rare: hemolytic uremic syndrome.
Avoid contact with aluminum (eg, needles). Formerly known under the brand name Paraplatin.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Improving Performance of Everyday Activities Is Critical in Schizophrenia
- Analysis Finds Lithium Maintenance Most Effective as Monotherapy in Bipolar Disorder
- Web-Based Intervention Targets Parental Behaviors That May Affect Adolescent Anxiety, Depression
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Examining Associations Between Diabetes and Effects on Cognition
- Untreated Depression Common in Women of Childbearing Age
- Incidence of Psychiatric Disorders in Rheumatoid Arthritis
- Effect of Antidepressant Class, Dose on Pediatric Anxiety Disorders